Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis

World Journal of Gastroenterology

Volumn 21, Issue 19, 2015, Pages 5985-5994

  Yoshimatsu, Yasushi ^a   Yamada, Akihiro ^a   Furukawa, Ryuichi ^a   Sono, Koji ^a   Osamura, Aisaku ^a   Nakamura, Kentaro ^a   Aoki, Hiroshi ^a   Tsuda, Yukiko ^a   Hosoe, Nobuo ^a   Takada, Nobuo ^a   Suzuki, Yasuo ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Cluster analysis; Inflammatory bowel disease; Probiotics; Ulcerative colitis

Indexed keywords

BACTERIAL DNA; BIO THREE; MESALAZINE; PLACEBO; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; STEROID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACILLUS PUMILUS; CLOSTRIDIUM BUTYRICUM; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; FECES ANALYSIS; FECES MICROFLORA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; REMISSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT DURATION; ULCERATIVE COLITIS; BACILLUS; COLITIS, ULCERATIVE; COLON; FECES; GENETICS; GROWTH, DEVELOPMENT AND AGING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; JAPAN; KAPLAN MEIER METHOD; MICROBIOLOGY; RECURRENT DISEASE; RIBOTYPING; TIME FACTOR; TREATMENT OUTCOME;

ADULT; BACILLUS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOSTRIDIUM BUTYRICUM; CLUSTER ANALYSIS; COLITIS, ULCERATIVE; COLON; DNA, BACTERIAL; DOUBLE-BLIND METHOD; ENTEROCOCCUS FAECALIS; FECES; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROBIOTICS; RECURRENCE; REMISSION INDUCTION; RIBOTYPING; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929630147     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i19.5985     Document Type: Article

References (54)

1. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'neil DA, Macfarlane GT. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005;54:242-249 [PMID: 15647189 DOI: 10.1136/gut.2004.044834]
2. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut 2001;48:132-135 [PMID: 11115835 DOI: 10.1136/gut.48.1.132]
3. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004;3:394-400 [PMID: 15288007 DOI: 10.1016/j.autrev. 2004.03.002]
4. Macfarlane GT, Furrie E, Macfarlane S. Bacterial milieu and mucosal bacteria in ulcerative colitis. Novartis Found Symp 2004;263:57-64; discussion 64-70, 211-218 [PMID: 15669634]
5. Cummings JH, Kong SC. Probiotics, prebiotics and antibiotics in inflammatory bowel disease. Novartis Found Symp 2004;263:99-111; discussion 111-114, 211-218 [PMID: 15669637]
6. Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003;52:79-83 [PMID: 12477765 DOI: 10.1136/gut.52.1.79]
7. Kanauchi O, Matsumoto Y, Matsumura M, Fukuoka M, Bamba T. The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease. Curr Pharm Des 2005;11:1047-1053 [PMID: 15777254 DOI: 10.2174/1381612053381675]
8. Tsuda Y, Yoshimatsu Y, Aoki H, Nakamura K, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol 2007;42:1306-1311 [PMID: 17852859 DOI: 10.1080/00365520701396091]
9. Nagashima K, Hisada T, Sato M, Mochizuki J. Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacterial populations in human feces. Appl Environ Microbiol 2003;69:1251-1262 [PMID: 12571054 DOI: 10.1128/AEM.69.2.1251-1262.2003]
10. Kibe R, Sakamoto M, Yokota H, Ishikawa H, Aiba Y, Koga Y, Benno Y. Movement and fixation of intestinal microbiota after administration of human feces to germfree mice. Appl Environ Microbiol 2005;71:3171-3178 [PMID: 15933018 DOI: 10.1128/AEM.71.6.3171-3178.2005]
11. Liu WT, Marsh TL, Cheng H, Forney LJ. Characterization of microbial diversity by determining terminal restriction fragment length polymorphisms of genes encoding 16S rRNA. Appl Environ Microbiol 1997;63:4516-4522 [PMID: 9361437]
12. Sakamoto M, Hayashi H, Benno Y. Terminal restriction fragment length polymorphism analysis for human fecal microbiota and its application for analysis of complex bifidobacterial communities. Microbiol Immunol 2003;47:133-142 [PMID: 12680716 DOI: 10.1111/j.1348-0421.2003.tb02796.x]
13. Sepehri S, Kotlowski R, Bernstein CN, Krause DO. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:675-683 [PMID: 17262808 DOI: 10.1002/ibd.20101]
14. Andoh A, Sakata S, Koizumi Y, Mitsuyama K, Fujiyama Y, Benno Y. Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:955-962 [PMID: 17455205 DOI: 10.1002/ibd.20151]
15. Johnson MW, Rogers GB, Bruce KD, Lilley AK, Von Herbay A, Forbes A, Ciclitira PJ, Nicholls RJ. Bacterial community diversity in cultures derived from healthy and inflamed ileal pouches after restorative proctocolectomy. Inflamm Bowel Dis 2009;15:1803-1811 [PMID: 19637361 DOI: 10.1002/ibd.21022]
16. Kohyama A, Ogawa H, Funayama Y, Takahashi K, Benno Y, Nagasawa K, Tomita S, Sasaki I, Fukushima K. Bacterial population moves toward a colon-like community in the pouch after total proctocolectomy. Surgery 2009;145:435-447 [PMID: 19303993 DOI: 10.1016/j.surg.2008.12.003]
17. Nishikawa J, Kudo T, Sakata S, Benno Y, Sugiyama T. Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis. Scand J Gastroenterol 2009;44:180-186 [PMID: 18825588 DOI: 10.1080/00365520802433231]
18. Ishikawa H, Matsumoto S, Ohashi Y, Imaoka A, Setoyama H, Umesaki Y, Tanaka R, Otani T. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion 2011;84:128-133 [PMID: 21525768 DOI: 10.1159/000322977]
19. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis 2011;5:115-121 [PMID: 21453880 DOI: 10.1016/j.crohns.2010.11.004]
20. Fujimori S, Gudis K, Mitsui K, Seo T, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition 2009;25:520-525 [PMID: 19201576 DOI: 10.1016/j.nut.2008.11.017]
21. Groeger D, O'Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes 2013;4:325-339 [PMID: 23842110 DOI: 10.4161/gmic.25487]
22. Andoh A, Shimada M, Araki Y, Fujiyama Y, Bamba T. Sodium butyrate enhances complement-mediated cell injury via downregulation of decay-accelerating factor expression in colonic cancer cells. Cancer Immunol Immunother 2002;50:663-672 [PMID: 11862418]
23. Andoh A, Fujiyama Y, Hata K, Araki Y, Takaya H, Shimada M, Bamba T. Counter-regulatory effect of sodium butyrate on tumour necrosis factor-alpha (TNF-alpha)-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells. Clin Exp Immunol 1999;118:23-29 [PMID: 10540155 DOI: 10.1046/j.1365-2249.1999.01038.x]
24. Den Hond E, Hiele M, Evenepoel P, Peeters M, Ghoos Y, Rutgeerts P. In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology 1998;115:584-590 [PMID: 9721155 DOI: 10.1016/S0016-5085 (98) 70137-4]
25. Steinhart AH, Hiruki T, Brzezinski A, Baker JP. Treatment of leftsided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 1996;10:729-736 [PMID: 8899080 DOI: 10.1046/j.1365-2036.1996.d01-509.x]
26. Roda A, Simoni P, Magliulo M, Nanni P, Baraldini M, Roda G, Roda E. A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon. World J Gastroenterol 2007;13:1079-1084 [PMID: 17373743 DOI: 10.3748/wjg.v13.i7.1079]
27. Hamer HM, Jonkers DM, Renes IB, Vanhoutvin SA, Kodde A, Troost FJ, Venema K, Brummer RJ. Butyrate enemas do not affect human colonic MUC2 and TFF3 expression. Eur J Gastroenterol Hepatol 2010;22:1134-1140 [PMID: 20461009 DOI: 10.1097/MEG.0b013e32833a6ca0]
28. Hamer HM, Jonkers DM, Vanhoutvin SA, Troost FJ, Rijkers G, De Bruïne A, Bast A, Venema K, Brummer RJ. Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr 2010;29:738-744 [PMID: 20471725 DOI: 10.1016/j.clnu.2010.04.002]
29. Hosoe N, Suzuki Y, Shirai K. [1-13C] sodium butyrate breath test in patients with active and quiescent ulcerative colitis by colonoscopic examination. Dig Absorpt 2008;31:43-47
30. Mitsui R, Ono S, Karaki S, Kuwahara A. Neural and non-neural mediation of propionate-induced contractile responses in the rat distal colon. Neurogastroenterol Motil 2005;17:585-594 [PMID: 16078948]
31. Mitsui R, Ono S, Karaki S, Kuwahara A. Propionate modulates spontaneous contractions via enteric nerves and prostaglandin release in the rat distal colon. Jpn J Physiol 2005;55:331-338 [PMID: 16336748 DOI: 10.2170/jjphysiol. RP000205]
32. Ono S, Karaki S, Kuwahara A. Short-chain fatty acids decrease the frequency of spontaneous contractions of longitudinal muscle via enteric nerves in rat distal colon. Jpn J Physiol 2004;54:483-493 [PMID: 15667672 DOI: 10.2170/jjphysiol.54.483]
33. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, Artis D, Xavier RJ, Teixeira MM, Mackay CR. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009;461:1282-1286 [PMID: 19865172]
34. Prantera C, Kohn A, Campieri M, Caprilli R, Cottone M, Pallone F, Savarino V, Sturniolo GC, Vecchi M, Ardia A, Bellinvia S. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther 2009;30:908-918 [PMID: 19678813 DOI: 10.1111/j.1365-2036.2009.04117.x]
35. Green JR, Gibson JA, Kerr GD, Swarbrick ET, Lobo AJ, Holdsworth CD, Crowe JP, Schofield KJ, Taylor MD. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment Pharmacol Ther 1998;12:1207-1216 [PMID: 9882028 DOI: 10.1046/j.1365-2036.1998.00427.x]
36. Miner P, Hanauer S, Robinson M, Schwartz J, Arora S. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 1995;40:296-304 [PMID: 7851193 DOI: 10.1007/BF02065413]
37. Courtney MG, Nunes DP, Bergin CF, O'Driscoll M, Trimble V, Keeling PW, Weir DG. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992;339:1279-1281 [PMID: 1349676 DOI: 10.1016/0140-6736 (92) 91601-4]
38. Giaffer MH, Holdsworth CD, Lennard-Jones JE, Rodrigues CA, McIntyre PB, Manjunatha S, Baron JH, Barrison IG, Polson RJ, Hoare AM. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther 1992;6:479-485 [PMID: 1358234]
39. Mulder CJ, Tytgat GN, Weterman IT, Dekker W, Blok P, Schrijver M, Van Der Heide H. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988;95:1449-1453 [PMID: 2903110]
40. Paoluzi OA, Iacopini F, Pica R, Crispino P, Marcheggiano A, Consolazio A, Rivera M, Paoluzi P. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 2005;21:1111-1119 [PMID: 15854173 DOI: 10.1111/j.1365-2036.2005.02458.x]
41. Järnerot G, Ström M, Danielsson A, Kilander A, Lööf L, Hultcrantz R, Löfberg R, Florén C, Nilsson A, Broström O. Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis. Aliment Pharmacol Ther 2000;14:1159-1162 [PMID: 10971232 DOI: 10.1046/j.1365-2036.2000.00821.x]
42. Kanauchi O, Mitsuyama K, Araki Y, Andoh A. Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr Pharm Des 2003;9:333-346 [PMID: 12570821 DOI: 10.217 4/1381612033391883]
43. Gionchetti P, Lammers KM, Rizzello F, Campieri M. VSL#3: an analysis of basic and clinical contributions in probiotic therapeutics. Gastroenterol Clin North Am 2005;34:499-513, ix-x [PMID: 16084310]
44. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539-1546 [PMID: 15984978 DOI: 10.1111/j.1572-0241.2005.41794.x]
45. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-114 [PMID: 14684584 DOI: 10.1136/gut.53.1.108]
46. Cui HH, Chen CL, Wang JD, Yang YJ, Cun Y, Wu JB, Liu YH, Dan HL, Jian YT, Chen XQ. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004;10:1521-1525 [PMID: 15133865]
47. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-1623 [PMID: 15479682 DOI: 10.1136/gut.2003.037747]
48. Kanauchi O, Suga T, Tochihara M, Hibi T, Naganuma M, Homma T, Asakura H, Nakano H, Takahama K, Fujiyama Y, Andoh A, Shimoyama T, Hida N, Haruma K, Koga H, Mitsuyama K, Sata M, Fukuda M, Kojima A, Bamba T. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol 2002;37 Suppl 14:67-72 [PMID: 12572869]
49. Bamba T, Kanauchi O, Andoh A, Fujiyama Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol 2002;17:818-824 [PMID: 12164955 DOI: 10.1046/j.1440-1746.2002.02709.x]
50. Mitsuyama K, Saiki T, Kanauchi O, Iwanaga T, Tomiyasu N, Nishiyama T, Tateishi H, Shirachi A, Ide M, Suzuki A, Noguchi K, Ikeda H, Toyonaga A, Sata M. Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study. Aliment Pharmacol Ther 1998;12:1225-1230 [PMID: 9882030]
51. Suzuki A, Mitsuyama K, Koga H, Tomiyasu N, Masuda J, Takaki K, Tsuruta O, Toyonaga A, Sata M. Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study. Nutrition 2006;22:76-81 [PMID: 16226014 DOI: 10.1016/j.nut.2005.04.013]
52. Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; (4): CD005573 [PMID: 17943867 DOI: 10.1002/14651858. CD005573.pub2]
53. Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2011; (12): CD007443 [PMID: 22161412 DOI: 10.1002/14651858. CD007443.pub2]
54. Sang LX, Chang B, Zhang WL, Wu XM, Li XH, Jiang M. Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J Gastroenterol 2010;16:1908-1915 [PMID: 20397271 DOI: 10.3748/wjg.v16.i15.1908]